1. Home
  2. INBS vs PHGE Comparison

INBS vs PHGE Comparison

Compare INBS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$4.07

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.54

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBS
PHGE
Founded
2016
2015
Country
United States
United States
Employees
N/A
57
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
INBS
PHGE
Price
$4.07
$0.54
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
160.8K
335.2K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
68.65
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
N/A
Revenue This Year
$778.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.25
52 Week High
$24.90
$8.50

Technical Indicators

Market Signals
Indicator
INBS
PHGE
Relative Strength Index (RSI) 72.23 21.64
Support Level $3.87 $0.48
Resistance Level $7.25 $0.60
Average True Range (ATR) 0.41 0.10
MACD 0.24 0.11
Stochastic Oscillator 61.43 7.44

Price Performance

Historical Comparison
INBS
PHGE

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: